Compare Amplitude Inc (AMPL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Mesoblast Limited — how do they compare? Amplitude Inc trades at $12.78 (market cap $1.52B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Amplitude Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| AMPL | MESO | |
|---|---|---|
Market Cap | $1.52B | $2.16B |
Sector | Technology | Technology |
52-Week High | $12.69 | $20.96 |
52-Week Low | $5.61 | $12.88 |
Enterprise Value | $1.39B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $11.26, up 4.55% in 24 hours, with a bullish technical signal and strong analyst support. Revenue growth is robust, reaching $343.21 million in 2025, but profitability remains a challenge with a net loss of $88.54 million. Recent news highlights investor conference participation and Q2 2026 results that met revenue estimates but missed on EPS.
The outlook is mixed: strong revenue growth and a $12.08 consensus price target suggest upside, but persistent losses, negative cash flow, and ongoing legal investigations pose significant risks. Investors should weigh growth potential against fundamental weaknesses and sentiment shifts from recent insider sales and legal scrutiny.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
